Review

The gut dysbiosis and immune system in atherosclerotic cardiovascular disease (ACVD)

Ji Youn Yoo1,*,†, Sarah Sniffen2,†, Kyle McGill Percy3, Veera Bramhachari Pallaval4, Booji Babu Chidipi5

1 College of Nursing, University of Tennessee, Knoxville, 1200 Volunteer Blvd, Knoxville, TN 37996, USA; jyoo14@utk.edu
2 Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610, USA; sarah.sniffen@ufl.edu
3 Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; kcm78@case.edu
4 Department of Biotechnology, Krishna University, Machilipatnam – 521004, Andhra Pradesh, India; veerabramha@gmail.com
5 Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 78, Tampa, FL, 33612, USA 5; chidipib@usf.edu
* Correspondence: jyoo14@utk.edu
† Both authors contributed equally to this work. Ji Youn Yoo and Sarah Sniffen equally contributed to the manuscript.

Abstract: Atherosclerosis is a leading cause of cardiovascular disease and mortality worldwide. Alterations in the gut microbiota composition, known as gut dysbiosis, have been shown to contribute to atherosclerotic cardiovascular disease (ACVD) development through several pathways. Disruptions in gut homeostasis are associated with activation of immune processes and systemic inflammation. The gut microbiota produces several metabolic products, namely trimethylamine (TMA), which is used to produce the proatherogenic metabolite trimethylamine-N-oxide (TMAO). Short chain fatty acids (SCFAs), including acetate, butyrate, and propionate, and certain bile acids (BAs) produced by the gut microbiota lead to inflammation resolution and decrease atherogenesis. Chronic low-grade inflammation is associated to common risk factors for atherosclerosis, including metabolic syndrome, type 2 diabetes mellitus (T2DM), and obesity. Novel strategies for reducing ACVD include the use of nutraceuticals such as resveratrol, modification of glucagon-like peptide 1 (GLP-1) levels, supplementation with probiotics, and administration of prebiotic SCFAs and BAs. Investigation into the relationship between the gut microbiota and its metabolites, and the host immune system could reveal promising insight into ACVD development, prognostic factors, and treatments.

Keywords: atherosclerotic cardiovascular disease (ACVD); atherosclerosis; gut dysbiosis; immune system; gut microbial metabolites; SCFAs; TMAO

Highlights

▪ Alterations of the gut microbial composition are associated with ACVD development.
▪ The gut microbiota interacts with the host immune system via its metabolic products to affect ACVD pathogenesis.
▪ Several metabolic diseases including diabetes and obesity are related to increased risk for ACVD.
▪ Therapies for reducing ACVD include administering resveratrol, prebiotics (SCFAs and BAs), probiotics, and GLP-1.

Introduction

Atherosclerosis is a condition characterized by plaque build-up within the arteries and thickening of the arterial walls. It is widely regarded as the leading cause of
cardiovascular disease (henceforth referred to as atherosclerotic cardiovascular disease (ACVD), which is currently the primary cause of death world-wide [1]. Obesity, diabetes, and metabolic syndrome are the most common factors contributing to increased risk of developing cardiovascular disease. Together with atherosclerosis, these comorbidities can contribute to an increased risk of myocardial infarction, cerebral infarction, and other cardiovascular diseases [2]. Nevertheless, the origin and pathogenesis of atherosclerosis remain unclear.

Over the last 20 years, numerous studies have emphasized the role inflammation plays in ACVD. Cholesterol deposition, inflammation, extracellular-matrix formation, and the gut microbiota elevate the risk of ACVD development. Understanding how the gut microbiota modulates risk factors for could yield predictive and prognostic data of extensive clinical utility [3-5]. The gut microbiota acts as a primary regulator of physiology and function, requisite for immune system development, regulation, and for maintaining intestinal homeostasis [6,7]. A healthy gut principally comprises the commensal bacterial phyla *Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria*, with *Firmicutes* and *Bacteroidetes* being the most prevalent. These enteric bacteria break down proteins and polysaccharides, synthesize vitamins, and generate a wide variety of metabolic products. This includes trimethylamine (TMA), which is converted to trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and bile acids (BAs). These metabolites are involved in regulating major host metabolic and immune pathways including interactions with immune cells such as dendritic cells (DCs), macrophages, and T cells [8]. However, when pathogenic bacteria dominate, as in gut dysbiosis conditions, these beneficial metabolic processes are disrupted. Therefore, manipulating the gut microbiota and its host-interactions has great potential for maintaining gut homeostasis, directly resulting in improved ACVD outcomes.

This review provides a synopsis of the experimental and clinical evidence for the crucial role the gut microbiota plays in ACVD. We assess how alteration of gut microbiota composition and gut metabolism leads to changes in the regulation of the immune system, resulting in the propagation of ACVD. Finally, this review emphasizes how new insights into the gut microbiota-ACVD relationship may lead to the expansion of therapeutic strategies for ACVD.

**Gut Dysbiosis in ACVD**

The resident bacteria of the gut can activate a wide variety of host activities. Dysbiosis of the gut is the common denominator in many risk factors for ACVD including lifestyle, dietary habits, aging, and obesity [9]. Recently, substantial interest has centered around how changing of the gut microbiota composition can lead to changes in the host metabolism, affecting ACVD pathogenesis. Depending on the metabolites present, pro- or anti-inflammatory processes are activated [9]. Therefore, atherosclerosis pathophysiology is made up of both metabolic and inflammatory aspects, which can both be affected by alterations in the gut microbiota composition.

The gut microbial community is largely composed of four phyla including *Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria* [10]. In a healthy gut, the anaerobic bacteria *Firmicutes* and *Bacteroidetes* constitute over 90% of the bacteria present in the gut, but the proportion of *Firmicutes* to *Bacteroidetes* differs across individuals [11,12]. This interindividual variation in bacterial composition can be attributed to differences in host genome and environmental factors, specifically stress level, the use of antibiotics, and diet [10]. Maintaining immune homeostasis is a highly demanding task, requiring differentiation between the multitude of beneficial microbes and the scant opportunistic pathogens. Gut homeostasis is achieved when the obligate anaerobic *Firmicutes* and *Bifidobacteriaceae*, which is family of *Actinobacteria*, dominate, whereas proliferation of facultative anaerobic *Enterobacteriaceae*, which is family of *Proteobacteria*, generally indicates gut dysbiosis [13].

Over time, it is becoming clearer that the interactions between the gut microbiota and the immune system leads to ACVD. Haraszthy et al. showed that atherosclerotic plaques
in human endarterectomy specimens contain various species of bacterial DNA such as Prevotella intermedia, Porphyromonas gingivalis, Actinobacillus actinomycetem comitans, and Bacteroides forsythus. Additionally, they found that periodontal pathogens and infectious microorganisms, such as Chlamydia pneumoniae, may contribute to the pathogenesis of atherosclerosis, leading to ACVD [14]. Ziyanshina and colleagues (2016) found that the order Burkholderiales and the genus Curvibacter were elevated in patients’ atherosclerotic plaque samples [15]. Voronina et al. showed that Burkholderiales and other members of Ralstonia and Propionibacterium represented the most elevated taxa within atherosclerotic plaques [16]. Some bacteria found in plaques were also associated with several clinical traits, such as alanine aminotransferase, total cholesterol, and fibrinogen levels [18]. Karlsson and colleagues (2012) demonstrated that gut microbiota, especially Collinsella, were abundant in symptomatic atherosclerosis patients [17]. Collinsella has been identified to affect the host metabolism via decreasing glycogenesis in the liver, changing cholesterol absorption in the gut, and increasing triglyceride synthesis [18]. Another important function of Collinsella was its ability to decrease the expression of tight junction proteins, leading to increased gut permeability [19]. Furthermore, Collinsella impacts the epithelial production of Interleukin 17A(IL-17A), C-X-C Motif Chemokine Ligand 1(CXCL1) and C-X-C Motif Chemokine Ligand 5(CXCL5) [19]. This may lead to neutrophil recruitment and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation, both of which contribute to the pathologic effects of disease-causing organisms in the gut [19]. Although the gut microbiota varies among individuals, the stable presence of core gut bacteria like Firmicutes and Bifidobacteriaceae seem to be required for normal gut function. In total, these studies indicate that several bacteria may influence the development of ACVD via multiple mechanisms.

The Immune System and ACVD

Although scientists are actively researching the connections between ACVD, the host immune system, and the trillions of gut bacteria, it has not been fully discovered yet [20]. In atherosclerosis, an initial insult to the endothelial lining leads to endothelial activation and structural alteration, resulting in plasma lipids, macrophages, and other leukocytes being recruited to the arterial wall [21]. Gut microbiota drive changes in the body's inflammatory state, thus altering atherogenesis. In healthy individuals, the gut bacteria and their metabolites work together to optimally respond to threats via the innate and adaptive immune responses [20,22]. Importantly, butyrate binds to GPR109a (a G protein-coupled receptor) on macrophages and DCs, decreasing the production of IL-6 and elevating the expression of the anti-inflammatory cytokine IL-10 [23]. This results in the development of T-regulatory (T_{reg}) cells while suppressing the proliferation of pro-inflammatory Th17 cells [24]. Butyrate has also been shown to regulate T_{reg} cells via forkhead box P3 (Foxp3) differentiation, which is essential for the suppression of several inflammatory responses [23,25]. Thus, one of the roles of butyrate in the immune response is enhancing anti-inflammatory processes and regulating the T_{reg} cells population to protect against systemic inflammation.

In ACVD, a large number of pro-inflammatory cytokines, including Interferon gamma (IFN-γ), IL-12, Transforming growth factor beta (TGF-β) and tumor necrosis factor-alpha (TNF-α) are evident in atherosclerotic plaques [26-28]. A greater ratio of pro-inflammatory to anti-inflammatory markers within atherosclerotic plaques may indicate accelerated plaque development and repressed inflammation resolution [29]. Several factors aid the switch between the pro- and anti-inflammatory phenotypes, including the transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ), a nuclear receptor mainly expressed in intestinal epithelial cells, which may be crucial for regulating atherogenesis. Chemokines and their receptors are expressed extensively throughout the body but are especially prominent in cells crucial to atherosclerosis development, including endothelial cells, smooth myocytes, and leukocytes. There, they promote
Atherosclerosis by selectively recruiting leukocytes and by activating G-protein coupled receptors (GPCRs), triggering chemotaxis [30].

Aside from their involvement in PPAR signaling, commensal bacteria also inhibit phagocyte migration, hence decreasing T- and B-cell activation. Commensal bacteria also initiate goblet cell differentiation, leading to the expansion of the protective mucosal layers. Contrarily, pathogenic bacteria activate DCs, which then trigger a specific T cell response including the differentiation of naïve T cells into Th1 and Th17 cells [31,32]. Lipo-polysaccharide (LPS), found in the cell membrane of gram-negative bacteria, contains several moieties including a core oligosaccharide, a lipid A moiety, and an O-antigen polysaccharide [33]. The lipid A moiety is recognized by toll-like receptors (TLRs), specifically the TLR4/MD-2 complex, which upon stimulation activates the innate immune response [34]. LPS serves as a representative pathogen-associated molecular pattern (PAMP) that can be used to identify specific bacterial pathogen invasion. Mucosal surface cells sense the presence of PAMPs through pattern recognition receptors (PRRs) triggering the innate immune response [34]. The other function of the polysaccharide moiety of LPS is to protect the pathogenic bacteria, both by preventing complement attacks or by camouflaging the bacteria with standard host carbohydrate residues [34]. This ability enables these bacteria to evade the host’s innate immune system, allowing for greater pathogenicity. However, an overabundance of SCFA-producing bacteria radically reduces the proliferation of gram-negative bacteria and therefore decreases LPS levels [35]. By influencing these various immune system responses, the gut microbiota can heavily impact the course of atherosclerotic development and perpetuation.

Many intracellular cascades are involved in ACVD pathophysiology, including Janus kinase (JAK) signal transducer, mitogen-activated protein kinase (MAPK), activator of transcription (STAT) and protein kinase B (Akt). Akt has an essential role in the proliferation and migration of endothelial cells, vascular penetration control, and angiogenesis within the vascular wall [36]. Knocking out Akt2, which is essential for metabolism, results in reduced glucose tolerance and increased insulin resistance, both hallmarks of ACVD [37-39]. JAK/STAT signaling is involved in a wide variety of essential cell processes but is particularly key for activating the cellular stress response. In cardiovascular disease, elevation of the STAT gene leads to foam-cell formation, atherosclerotic plaque development, and increased expression of pro-inflammatory signals [40]. The MAPKs also play a diverse role in cardiovascular physiology and are abundant in atherosclerotic lesions [41,42]. When researchers compared untreated groups to SB203580-treated groups – a known inhibitor of p38 MAPK, they found amplified gut inflammation, gut dysbiosis, and severe acute pancreatitis in the untreated groups. When analyzing the SB203580-treated group, the researchers found increased microbial diversity among the Bacteroidetes, Firmicutes, and Proteobacteria phyla [43]. This may be due to MAPKs known role in initiating the proinflammatory response, releasing cytokines, growth factors, and oxidative stress. Together these pathways shape the course of atherosclerotic lesion development both in the vasculature and in the gut.

The TMA/TMAO Pathway

The gut microbiota anaerobically breaks down fatty foods high in cholesterol, yielding the precursors phosphatidylcholine (PC) and L-carnitine. Gut microbial TMA lyases cut the C-N bond of PC or L-carnitine respectively, freeing the waste-product, TMA. It is then delivered to the liver, where a family of host hepatic enzymes, specifically the flavin monooxygenase3 (FMO3), oxidize TMA to form TMAO [44,45] (see Figure 1).
Figure 1. Mechanisms by which microbiota participate in atherosclerosis. The dietary nutrients choline and carnitine are selectively converted into TMA by opportunistic bacteria, such as *Prevotella*. TMA is transferred to the liver via portal circulation and oxidized by hepatic flavin monooxygenase 3 (FMO3), resulting in the production of TMA–N-oxide (TMAO). Increasing TMAO has been demonstrated to decrease bile acid pool size, impacting cholesterol metabolism via altered intestinal cholesterol transport, specifically reverse cholesterol transport (RCT). TMAO has also been associated with enhanced macrophage cholesterol accumulation and atherosclerosis development. Supplementation with pro/prebiotics, such as resveratrol, can increase butyrate-producing bacteria. With the increase in butyrate-producing bacteria, TMA producing bacteria become less prominent as they are outcompeted for resources. This results in increased levels of butyrate, which binds to G protein-coupled receptors (GPCRs) leading to decreased intestinal inflammation and an overall decreased risk of atherosclerosis, myocardial infarction, and cerebral infarction.

Wang et al. (2011) showed an association between the risk of atherosclerosis in humans and the plasma concentrations of choline, TMAO, and betaine, but also demonstrated their pro-atherogenic abilities in mice [7]. For example, supplementing mouse diets with betaine, choline, or TMAO, stimulated increased expression of several atherosclerosis-linked macrophage scavenger receptors, but only choline and TMAO supplementation, resulted in increased atherosclerosis. Additional germ-free mouse studies confirmed dietary choline and gut flora play a critical role in TMAO formation, accumulation of cholesterol in macrophages, and foam cell formation. Establishing a greater understanding of the connection between gut microbiota metabolism of dietary PC and ACVD development would improve the ability to create novel diagnostic tests and treatment options for ACVD [7]. In 2014, Tang and his colleagues observed higher fasting plasma TMAO levels in heart failure patients compared to age and gender-matched control groups. They also noted an especially robust negative prognosis associated with raised circulating TMAO levels among a group of stable heart failure patients that were incremental to classic risk factors, cardiorenal indicators, and signs of systemic inflammation [44]. Thus, this study provided evidence that gut microbiota-dependent TMAO generation may contribute to more than just the development and progression of CVD (see Table 1 supplementary).

Increased TMAO levels can be used as a prognostic tool for evaluating CVD risk [46-48]. Elevated TMAO is independently linked to the frequency of CVD and risks for MI, stroke, and death [49]. Likewise, increased plasma concentrations of betaine, choline, and carnitine are independently linked to increased risk of MI, stroke, and death. However, their predictive values are largely limited to individuals with concurrently raised TMAO.
levels [45]. One study demonstrated that TMAO levels are related to enrichment in the *Bacteroides* and *Prevotella* genera and showed that dietary TMAO supplementation encouraged a decline in total cholesterol absorption in mice. They also observed that TMAO precursors, choline and carnitine, along with TMAO repress reverse cholesterol transport (RCT) *in vivo* through intestinal microbiota dependent mechanisms [48]. Results from recent studies in high-fat diet fed mice indicates dietary TMAO supplementation might block hepatic insulin signaling, intensify diminished glucose tolerance, and augment inflammation in adipose tissue due to the upregulated expression of genes involved in these pathways [50]. Thus, TMAO can be directly linked to several comorbidities of ACVD.

To demonstrate the therapeutic potential of manipulating TMAO levels, Chen and colleagues (2016) found that resveratrol, a natural phytoalexin with prebiotic characteristics, diminished TMAO-induced atherosclerosis in ApoE knock-out mice. Simultaneously, resveratrol remodeled the gut microbiota, resulting in higher levels of the genera *Bifidobacterium* and *Lactobacillus*. This led to the inhibition of TMA production, and an overall reduction in TMAO levels. As a result, bile salt hydrolase (BSH) enzymatic activity increased, thus enhancing BA deconjugation and increasing fecal excretion [51]. When broad-spectrum antibiotics were administered to wild type mice, there was a near total suppression of TMAO levels due to intestinal flora suppression [7]. However, one month after removing antibiotic treatment, TMAO levels were once more detectable in plasma. Other mouse studies used a mix of several antibiotics and were able to inhibit dietary choline-accelerated atherosclerosis, suppress TMAO plasma concentrations, and inhibit macrophage foam cell development [9]. Unfortunately, despite this promising suppression of TMA-producing microbiota, chronic antibiotic use is not a feasible treatment option because it can result in resistant bacterial strains and repopulation (see Table 1).

**SCFAs and Inflammation**

Certain commensal intestinal bacteria, including *Anaerostipes butyraticus*, *Faecalibacterium prausnitzii*, and *Roseburia intestinalis*, digest complex carbohydrates and produce SCFAs, which supply an energy source for colonocytes and modulate the host immune system [52-54]. SCFAs are strongly related to reducing intestinal inflammation, preserving barrier stability, and protecting against pathogen invasion. The most prominent SCFAs are acetate, butyrate and propionate [55]. Their primary function is to regulate the immune response, largely via the generation of Treg cells and suppression of histone deacetylases (HDACs), both of which play crucial roles in atherosclerosis [56,57]. This SCFA-driven inhibition of HDACs suppresses the inflammatory response and consequently disrupts DC development [24,58]. Administration of SCFAs to peripheral blood mononuclear cells resulted in downregulated NF-κB activation and decreased pro-inflammatory cytokine production [59]. Thus, SCFAs ability to function as HDAC inhibitors may help regulate the inflammatory pathways in ACVD.

Additionally, research has implicated SCFAs as regulators of liver cholesterologenesis [60]. There is a marked difference in the hepatic metabolism of germ-free and bacteria colonized mice, potentially due to differences in the hepatic generation of SCFA’s [61]. In the liver of bacteria colonized mice, scientists observed evidence of increased triglyceride synthesis including elevated levels of stored triglycerides and triglyceride transporter production. This was accompanied by a decrease in fasting-induced adipose factor expression within the small intestine. One such factor, angioptiin-like 4 (ANGPTL4), normally inhibits the activities of lipoprotein lipase (LPL), including its mediation of adipose cell-triglyceride uptake [62]. ANGPTL4 has been identified as a downstream target of PPARs, agonists to which are extensively employed as treatments for CVD and T2DM [63,64]. PPAR-γ serves as the master regulator of adipocyte formation, whereas PPAR-α is primarily involved in hepatic fatty acid oxidation [63]. Of note, ANGPTL4 can be regulated by the gut microbiota [46]. When germ-free mice and ANGPTL4-deficient mice were fed a high-fat diet, they gained substantially greater body weight and adipose tissue compared to high-fat diet-fed colonized mouse controls. Thus, ANGPTL4 directly modulates...
the gut microbiome’s ability to regulate mouse adiposity [65,66]. Ingesting SCFA-producing bacteria may be a viable method for promoting the hepatic influx of SCFAs, yielding increased ANGPTL4 regulation, and consequently reducing the risk of developing ACVD.

Due to their anti-oxidative and pro-apoptotic properties, SCFAs can attenuate the oxidative and pro-inflammatory characteristics of ACVD. Aguilar and colleagues (2014) provided butyrate supplementation to several models of atherosclerosis: a human endothelial cell line and an ApoE knockout mouse model [67]. Butyrate impeded the development of atherosclerosis by increasing plaque stability and by diminishing the adhesion and migration of pro-inflammatory macrophages. Butyrate was also associated with reduced CD36 expression in macrophages and endothelial cells, the lowered activation of NF-κB, and the decreased release of pro-inflammatory cytokines [67]. Together, these studies solidify SCFA’s role as anti-inflammatory atheroprotective agents. Administering propionate, another SCFA, in mouse drinking water clearly attenuated hypertension, vascular inflammation and atherosclerosis, and cardiac damage in two different hypertensive cardiovascular damage mouse models [68]. This effect largely depended on propionate’s ability to regulate immune homeostasis, particularly with regard to Treg function. Marques et al. sought to disentangle which improvements in cardiovascular functions could be attributed to high fiber intake versus acetate [69]. Acetate, the most abundant of SCFAs, was effective at normalizing cardiac and renal hypertrophy and function, improving hypertension, as well as reducing left ventricular wall thickness in mice. It also led to decreases in body weight, which is an important risk factor for the development of atherosclerosis. Though acetate alone did not lead to changes in IL-1 signaling, fiber and acetate administration was associated with decreases in the transcription factor Egr1, reduction of which is commonly associated with protection from inflammation [69]. Thus, oral supplementation with propionate could improve cardiovascular indices in human patients.

**Bile acid (BA) Metabolism**

BAs are steroid acids produced by the liver and come in two forms. Primary BAs are directly synthesized from hepatic cholesterol and are conjugated with glycine, resulting in the production of chenodeoxycholic acid and cholic acid. These primary BAs ensure fats and vitamins are soluble and readily absorbed. Once the primary BAs pass into the duodenum, they are then reabsorbed into the distal ileum where they undergo deconjugation facilitated by the resident gut bacteria to form secondary BAs. BAs are involved in nutrient absorption and foreign substance disposal but can also act as signaling molecules [70]. They bind to and activate the nuclear hormone receptor farnesoid X receptors (FXRs) and G protein-coupled bile acid receptor (TGR5), which are strongly associated with impairing and maintaining glucose homeostasis in the body [71,72].

Activation of the TGR5s induces type 2 deiodinase activity in brown adipocytes, leading to enhanced energy expenditure. TGR5 is also involved in increasing glucagon-like peptide 1 (GLP-1) secretion from enteroendocrine cells. Together this results in improved glucose tolerance [73,74]. One study found that using a semisynthetic BA (INT-777) to activate macrophage TGR5s induced adenosine 3',5'-cyclic monophosphate (cAMP) signaling, subsequently inhibited NF-κB, and resulted in inhibited proinflammatory cytokine production. Miyazaki-Anzai et al. supported the importance of TGR5 and provided evidence for FXRs as anti-atherosclerotic targets. When they administered INT-767, a dual agonist of FXR and TGR5, they found it blocked classic atherosclerotic formation and decreased concentrations of the typical aortic cytokines and chemokines in low-density lipoprotein receptor knockout (LDLR−/−) mice with single deficiency of either FXR or TGR5. The anti-inflammatory and anti-atherogenic effects of INT-767 were completely obstructed when LDLR−/− mice were deficient in both FXR and TGR5. However, the ability to lower lipid levels was completely repressed when the mice were singularly FXR deficient, but not when singularly deficient in TGR5 [75]. This suggests that while FXR and TGR5 are both important for reducing atherosclerosis and inflammation,
FXR’s role in lowering lipids was not critical for INT-767’s ability to reduce atherosclerotic lesion size. Hu and colleagues (2018), used a high-fat diet rat model to demonstrate INT-767’s anti-inflammatory and anti-atherogenic effects. INT-767 exerted its anti-inflammatory effect by suppressing the TNF-α and NF-κB signaling pathways, significantly alleviating the liver damage caused by the high-fat diet [76]. This indicates that BA receptor activation is highly involved in modulating immune function and in preventing ACVD.

**Other Factors**

Chronic low-grade inflammation and T2DM have been strongly implicated as risk factors in the development of ACVD [6]. One of the hypotheses is that increased insulin resistance can result in compensatory hyperinsulinemia, which is one of the metabolic irregularities believed to underlie the pathophysiology of metabolic syndrome. Metabolic syndrome, in turn, is a precursor to ACVD [77]. Additionally, the excessive buildup of visceral fat, as in morbid obesity, is correlated with insulin resistance. This condition leads to raised production of pro-inflammatory cytokines and macrophage infiltration, fostering chronic low-grade inflammation and diminished immune-insulin interactions [78]. However, SCFAs can mitigate the T2DM-associated biological disruptions as they have demonstrated functional interactions with other endocrine hormones, such as leptin, ghrelin, peptide YY, and GLP-1. Specifically, SCFAs have demonstrably enhanced GLP-1 secretion. GLP-1 is an incretin hormone produced by the gut that is essential for glucose homeostasis. Following a meal, dietary fibers are metabolized into SCFAs, which then activate intestinal L-cells. These L-cells release GLP-1, which modulates glucagon release, hepatic gluconeogenesis, insulin secretion, insulin sensitivity, and central satiety [79]. Therapies, such as GLP-1, GLP-1 mimetics, and SCFAs, have been widely used to maintain body weight in obese individuals and to manage blood glucose levels in T2DM patients. Intravenous GLP-1 administered to T2DM patients reduces hyperglycemia and promotes insulin secretion via ion channel regulation. GLP-1 receptor agonists act as incretin mimetics and are linked with glucose-lowering effects, leading to a reduction in hemoglobin A1c (HbA1c) and consequently aiding in weight loss. Administration of an SCFA cocktail significantly elevated colonic GLP-1 secretion in rat and human L-cell lines [80]. Moreover, administering the butyrate-induced bacteria yielded therapeutic effects including protection against weight gain, increased GLP-1 secretion, and decreased insulin resistance [81]. How SCFAs enhance GLP-1 secretion is currently undetermined. It is believed that the free fatty acid receptors (FFAR)2 (GPR43) and FFAR3 (GPR41) promote GLP-1 secretion [80,82] (see Figure 2). Other studies showed that the SCFA-induced increase in GLP-1 secretion occurred independently of FFAR2 (GPR43) and FFAR3 (GPR41) expression in an animal model [83]. Continuing to explore the mechanisms by which GLP-1 alleviates diabetes-associated inflammation is critical for identifying potential therapeutic avenues and therefore reducing ACVD incidence.
SCFAs bring about system wide improvements in ACVD risk factors via GLP-1. Following food intake, dietary fibers are digested by gut microbiota into SCFAs including acetate, propionate, and butyrate. These SCFAs activate intestinal L-cells, leading to the release of GLP-1 both independently of and in conjunction with FFAR2 and FFAR3 activation. GLP-1 modulates a variety of organ functions including the liver, pancreas, and brain. It also systemically improves insulin sensitivity and glucose tolerance. This ability to improve various cardiovascular and metabolic risk factors for ACVD implicates GLP-1 and its synthetic mimetics as a viable treatment option for atherosclerosis.

Conclusion

The most common underlying cause of cardiovascular disease is the atherosclerotic process. This process is also related to risk factors, including chronic inflammation, diabetes, and obesity. The alteration of gut microbial composition leads to imbalances in the consequent levels of metabolites. Repeatedly, TMAO has been implicated in the progression of ACVD. Repressing TMAO producing bacteria has been shown to reduce the onset of dietary-choline-enhanced atherosclerosis in a mouse model. Higher fasting plasma TMAO levels have also been observed in heart failure patients compared to healthy controls. Additionally, TMAO precursors, choline, and carnitine, have been linked to reduced RCT. Meanwhile, elevated TMAO itself may aggravate many of the symptoms seen in consumers of a high-fat western diet, including insulin resistance. Similarly, suppression of SCFAs production can also lead to severe issues such as intestinal inflammation, decreased gut barrier integrity, reduced immune tolerance, and decreased protection against foreign pathogens. This can also cause dysregulation of liver cholesterol synthesis, macrophage polarization towards a pro-inflammatory phenotype, and reduced atherosclerotic plaque stability. Finally, when BA production is diminished then a variety of metabolic actions would be interrupted, such as the absorption of fats and vitamins, foreign substance disposal, glucose and lipid metabolism, regulation of the TNF-α and NF-κB signaling pathways, and the maintenance of glucose homeostasis. Together, the effects of these reductions in gut metabolites strongly suggest the gut microbiota is paramount in the development of ACVD.

Still, when looking into these various bacterial strains and the functions of their metabolic products, it is impossible to deny their strong connections to other diseases.
Obesity, diabetes, and metabolic syndrome are associated with gut dysbiosis and can also put an individual at a higher risk for developing ACVD. Potential treatment strategies for ACVD may help to mitigate the onset of these other risk factors. Ingesting SCFAs producing probiotics and administering antibiotics have both been shown to provide some degree of gut remodeling. This could lead to inhibition of the gut bacterial TMA production, increase BSH enzymes activity, and increase production of SCFA-producing bacteria. These treatment strategies may not be effective under prolonged use, and, as in the case of antibiotics, long term use could produce unwanted negative side effects. Therefore, it may be better to selectively target particular bacterial strains for upregulation or downregulation within the gut microbiota. Administering resveratrol as a prebiotic was successful in remodeling the gut microbiota and saw no negative side effects. Specific probiotic metabolites like SCFAs, BAs, or their derivatives have also been promising when used in cellular and animal models, but verification of their efficacy in humans is still necessary. As the prevalence of risk factors for ACVD continue to rise, there remains a critical need for further investigation into atherosclerosis treatments. This is especially important due to ACVD’s role as the most common cause of death worldwide. Carefully evaluating the gut microbiota-immune interactions will enable the identification of novel predictors of ACVD and the expansion of available treatment strategies, thus closing the gap between ACVD onset and availability of effective treatments.

Supplementary Materials: Table S1: The role of gut microbiota in TMA and TMAO pathways.

Author Contributions: Ji Youn Yoo and Sarah Sniffen equally contributed to the manuscript. Please indicate co-first authorship in the fine print of the published paper. Conceptualization: Ji Youn Yoo, Writing the Manuscript: Ji Youn Yoo, Sarah Sniffen, Kyle McGill Percy, Bojji Babu Chidipi, Veera Bramhachari Pallaval, Reviewing and Editing: Ji Youn Yoo, Sarah Sniffen, Kyle McGill Percy, Bojji Babu Chidipi, Veera Bramhachari Pallaval

Funding: This research received no external funding.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank Taylor Thor for his development of Figure 1 and 2.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

List of Abbreviations
Atherosclerotic cardiovascular disease (ACVD)
Angiopoietin-like 4 (ANGPTL4)
Adenosine 3’,5’-cyclic monophosphate (cAMP)
Bile acids (BAs)
Bile acid-activated nuclear hormone receptor farnesoid X receptor (FXR)
Cardiovascular diseases (CVD)
Flavin monoxygenases (FMOs)
Forkhead box protein P3 (Foxp3)
Glucagon-like peptide 1 (GLP-1)
G-protein-coupled receptors (GPCRs)
G protein-coupled bile acid receptor (TGR5)
Hemoglobin A1c (HbA1c)
Lipopolysaccharide (LPS)
Nuclear factor-κB (NF-κB)
Pattern recognition receptors (PRRs)
Peptide YY (PYY)
Peroxisome proliferator-activated receptors (PPARs)
Short-chain fatty acids (SCFAs)
Trimethylamine (TMA)
Trimethylamine-N-oxide (TMAO)
Tumor necrosis factor-alpha (TNF-α)
T-regulatory (Treg)
T helper 17 cell (Th17)
Toll-like receptors (TLRs)
Type 2 diabetes (T2DM)

References

1. Frostegård, J. Immunity, atherosclerosis and cardiovascular disease. *BMC Med* 2013, 11, 117, doi:10.1186/1741-7015-11-117.
2. Ross, R. Atherosclerosis—an inflammatory disease. *New England Journal of Medicine* 1999, 340, 115-126.
3. Sanz, J.; Fayad, Z.A. Imaging of atherosclerotic cardiovascular disease. *Nature* 2008, 451, 953-957, doi:10.1038/nature06803.
4. Arad, Y.; Goodman, K.J.; Roth, M.; Newstein, D.; Guerci, A.D. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. *J Am Coll Cardiol* 2005, 46, 158-165, doi:10.1016/j.jacc.2005.02.088.
5. Anderson, J.W. Whole grains protect against atherosclerotic cardiovascular disease. *Proc Nutr Soc* 2003, 62, 135-142, doi:10.1079/PNS20020222.
6. Yoo, J.Y.; Kim, S.S. Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders. *Nutrients* 2016, 8, 173, doi:10.3390/nu8030173.
7. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Brit, E.B.; Fu, X.; Chung, Y.M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011, 472, 57-63, doi:10.1038/nature09922.
8. Zhu, W.; Gregory, J.C.; Org, E.; Bufa, J.A.; Gupta, N.; Wang, Z.; Li, L.; Fu, X.; Wu, Y.; Mehrabian, M. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. *Cell* 2016, 165, 111-124.
9. Tang, W.W.; Kital, T.; Hazen, S.L. Gut microbiota in cardiovascular health and disease. *Circulation research* 2017, 120, 1183-1196.
10. Thursby, E.; Juge, N. Introduction to the human gut microbiota. *Biochemical Journal* 2017, 474, 1823-1836.
11. Faith, J.J.; Guruge, J.L.; Charbonneau, M.; Subramanian, S.; Seedorf, H.; Goodman, A.L.; Clemente, J.C.; Knight, R.; Heath, A.C.; Leibel, R.L. The long-term stability of the human gut microbiota. *Science* 2013, 341.
12. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichan, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T. A human gut microbial gene catalogue established by metagenomic sequencing. *nature* 2010, 464, 59-65.
13. Byrdloss, M.X.; Olson, E.E.; Rivera-Chávez, F.; Tiffany, C.R.; Cevallos, S.A.; Lokken, K.L.; Torres, T.P.; Byrdloss, A.J.; Faber, F.; Gao, Y. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. *Science* 2017, 357, 570-575.
14. Haraszthy, V.; Zambon, J.; Trevisan, M.; Zeid, M.; Genco, R. Identification of periodontal pathogens in atheromatous plaques. *Journal of periodontology* 2000, 71, 1554-1560.
15. Ziganshina, E.E.; Sharifullina, D.M.; Lozhkin, A.P.; Khayrullin, R.N.; Ignatyev, I.M.; Ziganshin, A.M. Bacterial communities associated with atherosclerotic plaques from Russian individuals with atherosclerosis. *PLoS One* 2016, 11, e0164836.
16. Voronina, O.L.; Kunda, M.S.; Ryzhova, N.N.; Aksenova, E.I.; Sharapova, N.E.; Semenov, A.N.; Amelina, E.L.; Chuchalin, A.G.; Gintsburg, A.L. On Burkholderiales order microorganisms and cystic fibrosis in Russia. *BM Genomics* 2018, 19, 74.
17. Karlsson, F.H.; Fåk, F.; Nookaew, I.; Tremaroli, V.; Fagerberg, B.; Petranovic, D.; Bäckhed, F.; Nielsen, J. Symptomatic atherosclerosis is associated with an altered gut metagenome. *Nature communications* 2012, 3, 1-8.
18. Gomez-Arango, L.F.; Barrett, H.L.; Wilkinson, S.A.; Callaway, L.K.; McIntyre, H.D.; Morrison, M.; Dekker Nitert, M. Low dietary fiber intake increases Collinsella abundance in the gut microbiota of overweight and obese pregnant women. *Gut Microbes* 2018, 9, 189-201.
19. Chen, J.; Wright, K.; Davis, J.M.; Jeraldlo, P.; Marietta, E.V.; Murray, J.; Nelson, H.; Matteson, E.L.; Taneja, V. An expansion of rare lineages of intestinal microbes characterizes rheumatoid arthritis. *Genome medicine* 2016, 8, 1-14.
20. Kau, A.L.; Ahern, P.P.; Griffin, N.W.; Goodman, A.L.; Gordon, J.I. Human nutrition, the gut microbiome and the immune system. *Nature* 2011, 474, 327-336, doi:10.1038/nature10213.
21. Sakakura, K.; Nakano, M.; Otsuka, F.; Ladich, E.; Kolodziej, F.D.; Virmani, R. Pathophysiology of atherosclerosis plaque progression. *Heart, Lung and Circulation* 2013, 22, 399-411.
22. Yoo, J.Y.; Groer, M.; Dutra, S.V.O.; Sarkar, A.; McSkimming, D.I. Gut Microbiota and Immune System Interactions. *Microorganisms* 2020, 8, 1587.
23. Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakaniishi, Y.; Uetake, C.; Kato, K.; Kato, T., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* 2013, 504, 446-450, doi:10.1038/nature12721.
24. Singh, N.; Gurav, A.; Sivaprakasam, S.; Brady, E.; Padia, R.; Shi, H.; Thangaraju, M.; Prasad, P.D.; Manicassamy, S.; Munn, D.H., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* 2014, 40, 128-139, doi:10.1016/j.immuni.2013.12.007.
25. Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veenen, J.; deRoos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.; Coffey, P.J., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013, 504, 451-455, doi:10.1038/nature12726.
26. McLaren, J.E.; Ramji, D.P. Interferon gamma: a master regulator of atherosclerosis. *Cytokine & growth factor reviews* 2009, 20, 125-135.
27. Hansson, G.K.; Libby, P. The immune response in atherosclerosis: a double-edged sword. *Nature reviews immunology* **2006**, *6*, 508-519.

28. Hansson, G.K.; Hermansson, A. The immune system in atherosclerosis. *Nature immunology* **2011**, *12*, 204-212.

29. Fadini, G.P.; Simonetti, F.; Cappellari, R.; Vitturi, N.; Galasso, S.; de Kreutzenberg, S.V.; Previato, L.; Avogaro, A. Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. *Atherosclerosis* **2014**, *237*, 805-808.

30. van der Vorst, E.P.; Döring, Y.; Weber, C. Chemokines and their receptors in Atherosclerosis. *Journal of Molecular Medicine* **2015**, *93*, 963-971.

31. Neal, M.D.; Leaphart, C.; Levy, R.; Prince, J.; Billiar, T.R.; Watkins, S.; Li, J.; Cetin, S.; Ford, H.; Schreiber, A., et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. *J Immunol* **2006**, *176*, 3070-3079, doi:10.4049/jimmunol.176.5.3070.

32. Morikawa, M.; Tsujibe, S.; Kiyoshima-Shibata, J.; Watanabe, Y.; Kato-Nagaoka, N.; Shida, K.; Matsumoto, S. Microbiota of the small intestine is selectively phagocytosed by phagocytes of the lamina propria and Peyer’s patches. *PloS one* **2016**, *11*, e0163607, doi:10.1371/journal.pone.0163607.

33. Raetz, C.R.; Reynolds, C.M.; Trent, M.S.; Bishop, R.E. Lipid A modification systems in gram-negative bacteria. *Annu. Rev. Biochem.* **2007**, *76*, 295-329.

34. Matsuura, M. Structural modifications of bacterial lipopolysaccharide that facilitate gram-negative bacteria evasion of host innate immunity. *Frontiers in immunology* **2013**, *4*, 109.

35. Gu, W.; Wang, Y.; Zeng, L.; Dong, J.; Bi, Q.; Yang, X.; Che, Y.; He, S.; Yu, J. Polysaccharides from Polygonatum kingianum and their immunomodulatory effects on rats fed a high fat diet. *Biomedicine & Pharmacotherapy* **2020**, *125*, 109910.

36. Ackah, E.; Yu, J.; Zoeller, S.; Ikawari, Y.; Skurk, C.; Shibata, R.; Ouchi, N.; Easton, R.M.; Galasso, G.; Birnbaum, M.J., et al. Akt1/protein kinase Balph is critical for ischemic and VEGF-mediated angiogenesis. *J Clin Invest* **2005**, *115*, 2119-2127, doi:10.1172/JCI24726.

37. Tschopp, O.; Yang, Z.Z.; Brodbeck, D.; Dummler, B.A.; Hemmings-Mieszczak, M.; Watanabe, T.; Michaelis, T.; Frahm, J.; Hemmings, B.A. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. *Development* **2005**, *132*, 2943-2954, doi:10.1242/dev.01864.

38. Easton, R.M.; Cho, H.; Roovers, K.; Shirneman, D.W.; Mizrahi, M.; Lee, V.M.; Szabolcs, M.; de Jong, R.; Oltersdorf, T., et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. *Mol Cell Biol* **2005**, *25*, 1869-1878, doi:10.1128/mcb.25.5.1869-1878.2005.

39. Cho, H.; Thorvaldsen, J.L.; Chu, Q.; Feng, F.; Birnbaum, M.J. Akt1/PKBalp is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. *J Biol Chem* **2001**, *276*, 38349-38352, doi:10.1074/jbc.C100462200.

40. Szeg, M.; Piszsky-Borychowska, A.; Plens-Galaska, M.; Wesoly, J.; Bluyssen, H.A.R. Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. *Oncotarget* **2016**, *7*, 48788-48812, doi:10.18632/oncotarget.9195.

41. Reustle, A.; Torzewski, M. Role of p38 MAPK in Atherosclerosis and Aortic Valve Sclerosis. *International journal of molecular sciences* **2018**, *19*, 3761, doi:10.3390/ijms19123761.

42. Muslin, A.J. MAPK signaling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. *Clin Sci (Lond)* **2008**, *115*, 203-218, doi:10.1042/CS20070430.

43. Han, Y.; Zhu, R.-X.; Pan, X.-Y.; Han, Z.-Z.; Pan, X.-T. Improvement of Gut Microbiota by Inhibition of P38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Rats with Severe Acute Pancreatitis. *Med Sci Monit* **2019**, *25*, 4609-4616, doi:10.12659/MSM.914538.

44. Tang, W.W.; Wang, Z.; Fan, Y.; Levison, B.; Hazen, J.E.; Donahue, L.M.; Wu, Y.; Hazen, S.L. Prognostic value of elevated levels of intestinal microbe-generated metabolite N-Oxide-p in patients with heart failure: refining the gut hypothesis. *Journal of the American College of Cardiology* **2014**, *63*, 1908-1914.

45. Tang, W.W.; Hazen, S.L. The contributory role of gut microbiota in cardiovascular disease. *The Journal of clinical investigation* **2014**, *124*, 4204-4211.

46. Bäckhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenovkovich, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the national academy of sciences* **2004**, *101*, 15718-15723.

47. Koeth, R.A.; Wang, Z.; Levison, B.S.; Buffa, J.A.; Org, E.; Sheehy, B.T.; Britt, E.B.; Fu, X.; Wu, Y.; Li, L., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* **2013**, *19*, 576-585, doi:10.1038/nm.3145.

48. Koeth, R.A.; Levison, B.S.; Culley, M.K.; Buffa, J.A.; Wang, Z.; Gregory, J.C.; Org, E.; Wu, Y.; Li, L.; Smith, J.D. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. *Cell metabolism* **2014**, *20*, 799-812.

49. Tang, W.H.; Wang, Z.; Levison, B.S.; Koeth, R.A.; Britt, E.B.; Fu, X.; Wu, Y.; Hazen, S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med* **2013**, *368*, 1575-1584, doi:10.1056/NEJMoa109400.

50. Gao, X.; Liu, X.; Xu, J.; Xue, C.; Xue, Y.; Wang, Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. *Journal of bioscience and bioengineering* **2015**, *119*, 805-808.

51. Chen, M.-I.; Li, Y.; Zhang, Y.; Zhou, X.; Ran, L.; Yang, J.; Zhu, J.-d.; Zhang, Q.-y.; Mi, M.-t. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherothrombosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. *MBio* **2016**, *7*.
53. Macfarlane, G.; Gibson, G. Microbiological aspects of the production of short-chain fatty acids in the large bowel. *Physiological and clinical aspects of short-chain fatty acids* 1995, 87-105.

54. Flint, H.J.; Scott, K.P.; Duncan, S.H.; Louis, P.; Forano, E. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes* 2012, 3, 289-306, doi:10.4161/gmic.19897.

55. Chambers, E.S.; Preston, T.; Frost, G.; Morrison, D.J. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. *Current nutrition research* 2018, 7, 198-206.

56. Zheng, X.-x.; Zhou, T.; Wang, X.-A.; Tong, X.-h.; Ding, J.-w. Histone deacetylases and atherosclerosis. *Atherosclerosis* 2015, 240, 355-366.

57. Arpaia, N.; Campbell, C.; Fan, X.; Dikty, S.; van der Veeken, J.; Deroos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.; Coffer, P.J. Metabolites produced by commensal bacteria promote complex regulatory-T cell generation. *Nature* 2013, 504, 451-455.

58. Liacciardi, P.V.; Ververis, K.; Karagiannis, T.C. Histone deacetylase inhibition and dietary short-chain Fatty acids. *ISRN Allergy* 2011, 2011, 869647, doi:10.5402/2011/869647.

59. Usami, M.; Kishimoto, K.; Ohata, A.; Miyoshi, M.; Aoyama, M.; Fueda, Y.; Kotani, J. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. *Nutr Res* 2008, 28, 321-328, doi:10.1016/j.nutres.2008.02.012.

60. Trautwein, E.A.; Rieckhoff, D.r.; Erbersdobler, H.F. Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters. *The Journal of nutrition* 1998, 128, 1937-1943.

61. Gäbel, G.; Aschenbach, J.; Müller, F. Transfer of energy substrates across the ruminal epithelium: implications and limitations. *Animal health research reviews* 2002, 3, 15.

62. Sukonina, V.; Lookene, A.; Olivecrona, T.; Olivecrona, G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates adipose tissue lipase activity in tissue. *Proceedings of the National Academy of Sciences* 2006, 103, 17450-17455.

63. Kersten, S.; Mandard, S.; Tan, N.S.; Escher, P.; Metzger, D.; Chambon, P.; Gonzalez, F.J.; Desvergne, B.; Wahli, W. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. *Journal of Biological Chemistry* 2004, 279, 26488-26493.

64. Ferré, P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. *Diabetes* 2004, 53, S43-S50.

65. Mattjissen, F.; Alex, S.; Swarts, H.J.; Groen, A.K.; van Schothorst, E.M.; Kersten, S. Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion. *Molecular metabolism* 2014, 3, 135-144.

66. Tremaroli, V.; Bäckhed, F. Functional interactions between the gut microbiota and host metabolism. *Nature* 2012, 489, 242-249.

67. Aguilar, E.; Leonel, A.; Teixeira, L.; Silva, A.; Silva, J.; Pelaez, J.; Capettini, L.; Lemos, V.; Santos, R.; Alvarez-Leite, J. Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFXs activation. *Nutrition, Metabolism and Cardiovascular Diseases* 2014, 24, 606-613.

68. Bartolomaeus, H.; Balogh, A.; Yakoub, M.; Homann, S.; Markó, L.; Höges, S.; Tsvetkov, D.; Kranich, A.; Wundersitz, S.; Avery, E.G., et al. Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage. *Circulation* 2019, 139, 1407-1421, doi:10.1161/circulationaha.118.036652.

69. Marques, F.Z.; Nelson, E.; Chu, P.Y.; Horlock, D.; Fiedler, A.; Ziemann, M.; Tan, J.K.; Kuruppu, S.; Rajapakse, N.W.; El-Osta, A., et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. *Circulation* 2017, 135, 964-977, doi:10.1161/circulationaha.116.024545.

70. Chiang, J.Y. Bile acid signaling and metabolism. *Comprehensive Physiology* 2013, 3, 1191-1212.

71. Pellicciari, R.; Sato, H.; Gioiello, A.; Costantino, G.; Macchiarlo, A.; Sadeghpour, B.M.; Giorgi, G.; Schoonjans, K.; Auwerx, J. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23-and 6, 23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. *Journal of medicinal chemistry* 2007, 50, 4265-4268.

72. Wang, X.X.; Luo, Y.; Wang, D.; Adorini, L.; Puzanski, M.; Dobrinskikh, E.; Levi, M. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. *Journal of Biological Chemistry* 2017, 292, 12018-12024.

73. Watanabe, M.; Houten, S.M.; Mataka, C.; Christoffolete, M.A.; Kim, B.W.; Sato, H.; Messaddeq, N.; Harney, J.W.; Ezaki, O.; Kodama, T. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 2006, 439, 484-489.

74. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarlo, A.; Yamamoto, H.; Mataka, C.; Puzanski, M. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell metabolism* 2009, 10, 167-177.

75. Miyazaki-Anzai, S.; Masuda, M.; Kohno, S.; Levi, M.; Shiozaki, Y.; Keenan, A.L.; Miyazaki, M. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. *Journal of lipid research* 2018, 59, 1709-1713.

76. Hu, Y.-B.; Liu, X.-Y.; Zhan, W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. *Drug design, development and therapy* 2018, 12, 2213.

77. de Luca, C.; Olefsky, J.M. Inflammation and insulin resistance. *FEBS Lett* 2008, 582, 97-105, doi:10.1016/j.febslet.2007.11.057.

78. Wang, J.; Tang, H.; Zhang, C.; Zhao, Y.; Derrien, M.; Rocher, E.; van-Hylckama Vlieg, J.E.; Strissel, K.; Zhao, L.; Obin, M., et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat-fed mice. *ISME J* 2015, 9, 1-15, doi:10.1038/ismej.2014.99.

79. Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F., et al. Glucagon-like peptide 1 (GLP-1). *Mol Metab* 2019, 30, 72-130, doi:10.1016/j.molmet.2019.09.010.
80. Tolhurst, G.; Heffron, H.; Lam, Y.S.; Parker, H.E.; Habib, A.M.; Diakogiannaki, E.; Cameron, J.; Grosse, J.; Reimann, F.; Gribble, F.M. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes 2012*, 61, 364-371, doi:10.2337/db11-1019.

81. Yadav, H.; Lee, J.H.; Lloyd, J.; Walter, P.; Rane, S.G. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. *J Biol Chem 2013*, 288, 25088-25097, doi:10.1074/jbc.M113.452516.

82. Ducastel, S.; Touche, V.; Trabelsi, M.-S.; Boulinguez, A.; Butruille, L.; Nawrot, M.; Peschard, S.; Chávez-Talavera, O.; Dorchies, E.; Vallez, E. The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids. *Scientific reports 2020*, 10, 1-10.

83. Christiansen, C.B.; Gabe, M.B.N.; Svendsen, B.; Dragsted, L.O.; Rosenkilde, M.M.; Holst, J.J. The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. *American Journal of Physiology-Gastrointestinal and Liver Physiology 2018*, 315, G53-G65.